(Stroke. 1997;28:1501-1506.)
© 1997 American Heart Association, Inc.
Articles |
| Introduction |
|---|
|
|
|---|
Mostbut not allstrokes have a sudden or rapidly evolving onset. Differential diagnosis of sudden change in focal neurological status includes seizures or postepileptic paralysis, hemorrhage into a tumor (itself a form of stroke), and migraine. Neuroimaging helps to differentiate between these and the cause of short-lived symptoms (transient ischemic attack [TIA]) usually presumed due to ischemia but possibly due to new-onset infarction or hemorrhage. More precise classification of stroke into a pathogenic subtype (embolism, thrombosis, decreased perfusion or "lacunar" infarction, leakage, or rupture) evades the best clinical skills.
| Diagnosis of Ischemic Stroke Mechanism |
|---|
|
|
|---|
The currently recognized ischemic stroke mechanisms are
embolism, decreased perfusion, and thrombosis. Lacunar infarction
(infarct size
1.5 cm) may be caused by all three mechanisms but in
"crisp" stroke subtype classifications has been named either a
cause or a mechanism of ischemic stroke.
| Embolism to the Brain of Cardiac or Aortic Origin |
|---|
|
|
|---|
Myocardial Infarction
Stroke is an important complication in patients with AMI,
occurring in 1% to 3% of all infarctions and in 2% to 6% of
patients with anterior wall infarctions. The majority of strokes after
AMI are thought to be embolic, arising from left
ventricular wall mural thrombi, but a number may be
atherothrombotic or, in the acute phase, secondary to
hemodynamic compromise. Most strokes occur in the first
weeks after the infarct, but some risk for stroke remains for an
indefinite time. Echocardiographic studies have
demonstrated that left ventricular mural thrombosis occurs
in up to 40% of patients with anterior wall MI, particularly in
association with wall motion abnormalities. Mural thrombosis is
uncommon with inferior wall MI. Risk factors for left
ventricular mural thrombosis are large infarctions, left
ventricular dilation, or congestive heart failure. Atrial
fibrillation may occur after AMI as an independent risk factor. The
original studies comparing anticoagulant therapy with heparin and
warfarin in the treatment of AMI showed, in addition to reduction in
mortality and recurrent infarction, a large reduction in risk of
stroke.
More recent long-term studies with oral anticoagulants in patients who survived AMI showed a reduction in risk of stroke of 40% to 50% over a 3-year period. The reduction in risk of stroke with oral anticoagulant therapy is greater than that demonstrated with aspirin, the most widely used antithrombotic treatment following AMI. Bleeding events, including intracerebral bleeding, are an uncommon but serious occurrence in patients treated with long-term oral anticoagulants. The rate for intracranial bleeding in long-term studies is approximately 1% per year. Patients identified as being at high risk for systemic embolism are similar to those at risk for left ventricular mural thrombosis. The presence of left ventricular mural thrombosis increases the risk of stroke.
Anticoagulation in the acute phase of MI reduces the risk of left ventricular mural thrombosis. Thrombolysis in combination with aspirin has resulted in a reduction in mortality of 40% to 50%. However, there is an increased risk of intracranial hemorrhage with thrombolysis. Factors that increase that risk are advanced age, hypertension, previous stroke, and use of tissue plasminogen activator (TPA).
There is no evidence that thrombolysis alone affects the risk of left ventricular mural thrombosis. Based on current evidence, anticoagulant therapy with a target international normalized ratio (INR) of 2.5 to 3.5 is recommended in patients at high risk for systemic embolism for 6 months after AMI.
| Selected Reading |
|---|
|
|
|---|
Atrial Fibrillation
Cerebral infarction in a patient with atrial fibrillation is
presumed to result from embolization of intracardiac thrombi, which
most commonly form in the left atrial appendage. Autopsy data indicate
that stroke is a possibility throughout the life of persons with a
history of atrial fibrillation. Duration of atrial fibrillation has not
correlated with risk, and intermittent atrial fibrillation seems as
great a risk as persistent atrial fibrillation.
The results of several prospective randomized stroke prevention trials show that the relative risk of stroke in atrial fibrillation patients can be reduced by up to 70% using oral anticoagulant therapy. The risk of major hemorrhage attributable to anticoagulation therapy was typically between 0.5% and 1.0% per year. The optimal intensity of anticoagulation appears to be an INR of 2.0 to 3.0.
Compared with placebo in prospective randomized trials, aspirin provides a reduction in risk of approximately 20% to 25%. In additional trials, when aspirin was compared directly with oral anticoagulation, it was found to be approximately 50% as effective as warfarin for preventing ischemic stroke. Aspirin is associated with a risk of major bleeding, estimated to be two thirds that of warfarin. Patients with atrial fibrillation associated with previous thromboembolism, hypertension, and congestive heart failure have a stroke risk of approximately 20% per year. In this group, anticoagulation provides an absolute reduction in risk of stroke of approximately 13% per year, even after accounting for the risk of major hemorrhage.
Brief isolated episodes of atrial fibrillation are not uncommon after cardiac surgery; these patients, who have not been shown to be at an increased risk of future stroke, were excluded from the atrial fibrillationstroke prevention trials. Patients with atrial fibrillation and mechanical heart valves have also been excluded from the randomized trials because it has been an established clinical practice that anticoagulation is required for these persons regardless of age or associated cardiovascular disorders.
In a patient with atrial fibrillation who has acute stroke, recurrent stroke risk may be particularly high during the first week or two after the acute infarction. Immediate anticoagulation of acute cardioembolic infarct carries a risk of hemorrhagic transformation with clinical deterioration. For patients at high risk of recurrent embolism (such as those with mechanical heart valves, established intracardiac thrombus, or atrial fibrillation associated with mitral stenosis or congestive heart failure), early anticoagulation is generally recommended, especially if the acute infarct is not large and the patient does not have uncontrolled hypertension. For patients at relatively low risk for early recurrence, delaying anticoagulation for several days to a week may reduce the risk of early hemorrhagic deterioration, particularly for patients with large infarcts or uncontrolled hypertension.
| Selected Reading |
|---|
|
|
|---|
Valvular Disease
Ischemic stroke is a well known complication of cardiac
valvular pathology. Its pathogenesis is generally accepted to
be an embolism from the diseased native valve or the prosthetic
valve that replaced it.
Native Valves
Of mitral and aortic valve disorders, rheumatic mitral
stenosis is the most common associated with thromboembolism,
irrespective of the coexistence of mitral
regurgitation. Atrial fibrillation increases the risk
of thromboembolism up to 18 times. Thrombi associated with mitral
stenosis can be found on either the atrial wall or in its
appendage. The risk of thromboembolism in rheumatic valve
stenosis is related to age and low cardiac output, yet it does
not correlate well with left atrial size, mitral calcification, or
severity of mitral stenosis. The association of mitral
regurgitation with thromboembolism correlates with the
coexistence of mitral stenosis.
Oral anticoagulation reduces risk of stroke in patients with rheumatic mitral stenosis, particularly those with coexistent atrial fibrillation. The risk-benefit ratio in those without atrial fibrillation is not known. The benefit of antiplatelet agents in the prevention of stroke in patients with any type of rheumatic valvular disease has not been established. Of those patients who have had one event, early recurrent embolism has been reported in up to two thirds and aggressive anticoagulation instituted.
Mitral Valve Prolapse
Autopsy series have shown that patients with mitral valve prolapse
(MVP) have fibrinous deposits on the valve, endothelial
denudation, or annular thrombus at the junction with the atrial wall.
Myxomatous and redundant valve leaflets seem to be more prone to
production of thromboembolic events. Patients with MVP who are
asymptomatic are not necessarily candidates for
antithrombotic or anticoagulant agents. Those who have suffered
ischemic brain events should be given prophylactic
medication. Antiplatelet agents are used for MVP; long-term
anticoagulation is reserved for patients who do not respond or have
significant valvular dysfunction.
Mitral annulus calcification has been associated with mitral stenosis, mitral regurgitation, conduction abnormalities, arrhythmias, and cardiogenic brain embolism. Identification by echocardiography, irrespective of the coexistence of atrial fibrillation, suggests a twofold increase in risk for stroke. Association with embolism of fibrinated cell clot or calcium spicules has been reported.
Despite reports that show the potential for clots to form on the leaflets of aortic valves and the number of systemic emboli found in autopsy series included in this population (approaching 20%), the incidence of clinically evident events is small. Emboli associated with aortic insufficiency are most commonly seen in patients who also have endocarditis, atrial fibrillation, or coexistent mitral pathology.
Prosthetic Heart Valves
Diseased heart valves are replaced with either mechanical or
bioprosthetic (tissue) valves. Tissue prosthetic valves
are believed to be associated with a smaller risk of thromboembolism
than mechanical valves. Mitral valve prostheses are associated with a
greater risk of thromboembolism, possibly because of the higher
incidence of atrial fibrillation and other thromboembolic risk factors
in these patients.
Repaired Cardiac Valves
In general, surgical repair of mitral valves for mitral
insufficiency has been reported to be longer lasting and to have lower
morbidity and mortality and lower incidence of thromboembolism than
valvular replacement. Percutaneous balloon
valvuloplasty of the mitral valve continues to be associated with
significant risk for embolization, despite systemic administration of
heparin and careful selection of patients. Aortic valvuloplasty leads
to fewer long-lasting beneficial effects and is currently reserved for
patients who are poor candidates for surgery. Despite all precautions,
the risk of stroke is approximately 2%.
| Selected Reading |
|---|
|
|
|---|
Patients with mechanical prosthetic valves must receive lifelong anticoagulation with warfarin. The current recommended level of anticoagulation is an INR of 2.5 to 3.5. The addition of antiplatelet agents to this regimen reduces the risk of thromboembolism from prosthetic heart valves. Although it is believed that bioprosthetic valves carry a lesser risk of thromboembolism, at least two studies have failed to confirm lower risk. Anticoagulation is recommended for the first 3 months after valve replacement, after which antiplatelet agents can be used.
Embolism of Aortic Arch Origin
Complicated atherosclerotic plaques of the aortic arch constitute
a source of atherothrombolic or cholesterol embolism.
Transesophageal echocardiography
(TEE) allows detection of plaques in the aortic arch. A causal link
between brain infarcts and complicated plaques with highly mobile
thrombi in the lumen of the aortic arch is likely. Plaques without
mobile components might merely be markers for diffuse
atherosclerosis. Recent work has established a
statistical link between the presence of atherosclerotic disease in the
aortic arch and ischemic stroke. The highest risk of
ischemic stroke is associated with plaques >4 mm in the
proximal archan independent risk factor even when the presence of
carotid stenosis and atrial fibrillation are taken into
account. Superimposed thrombotic material, as well as actual plaque,
may be included within the measurement of the "plaque thickness"
made with TEE. The presence of a thrombus may explain the more frequent
mobile component in patients with plaques >4 mm in thickness.
The annual risk of recurrent ischemic stroke may be as high as 12% per year in patients with aortic arch plaques >4 mm; risk of stroke, MI, peripheral embolism, and vascular events is 26% per year. TEE is accurate, safe, and well tolerated for examination of the aortic arch, even in patients older than 85 years. Treatment with oral anticoagulants, platelet antiaggregants, and surgery to remove the plaque are all options whose relative superiority has not been determined.
| Selected Reading |
|---|
|
|
|---|
Patent Foramen Ovale
The diagnosis of a patent foramen ovale may be suspected in any
stroke patient. Detection of a patent foramen ovale and a right-to-left
(ie, venous-to-arterial) shunt can be appreciated by TEE
(which insonates the atria easily, is preferred over the
transthoracic route, and better insonates the
ventricular chambers). Transcranial
Doppler, using agitated saline injected into a convenient vein
(usually the antecubital), may show the emergence of echogenic
microbubbles in the brain circulation. It is not known if the stroke
rate is dependent on characteristics of the patent foramen ovale, eg,
size, spontaneous shunting, and shunting with Valsalva maneuver. A
concomitant hypercoagulable state may be important. Whether
antiplatelet or anticoagulant agents are most effective in
prevention of recurrent stroke is unknown. When the patent foramen
ovale is large, surgical closure may be an option. Catheter placement
of a prosthetic device to block the foramen is in
development.
| Selected Reading |
|---|
|
|
|---|
| Cerebral Ischemia Due to Perfusion Failure and Artery-to-Artery Embolism |
|---|
|
|
|---|
Large Artery Atherosclerotic Plaque
Pathology studies show that atherosclerotic lesions are not
randomly distributed along the cerebral arterial tree. The
carotid artery system is mostly affected at the common carotid artery
bifurcation, the siphon, and the M1 segment of the middle cerebral
artery. Along the vertebrobasilar circulation, the first and fourth
segments of the vertebral artery and the first segment of the basilar
artery are frequently affected. Factors that lead these lesions to
become symptomatic are not well understood, but
stenoses >70% are linearly associated with increased risk of
distal brain infarct.
Cooperative studies have shown that in symptomatic patients with >70% carotid stenosis, carotid endarterectomy is effective in reducing the risk of subsequent ipsilateral stroke. The accuracy of cerebral angiography in determining the severity of stenosis of extracranial and intracranial lesions has been questioned. There is no consensus regarding a method to measure the degree of stenosis from radiographic films. It is frequently impossible to differentiate between recanalized emboli, thrombi, and actual atherosclerotic plaque at the site of artery occlusion. Angiography is considered the gold standard for assessment of the cerebral vasculature. Magnetic resonance angiography, color duplex, and transcranial Doppler are acceptable noninvasive techniques to screen patients with suspected lesions.
Artery-to-artery embolism is thought to be the most common cause of cerebral infarction associated with plaques of the large cerebral arteries. Watershed infarcts secondary to the hemodynamic compromise may be less common. In situ thrombosis may occur. Embolic infarcts associated with these plaques usually involve the middle and posterior artery territories and vary in size. These lesions tend to involve the cerebral cortex and frequently are wedge-shaped on neuroimaging studies.
Vasculitis
Inflammatory conditions can involve the cerebral vasculature.
Some, like granulomatous angiitis, are primarily limited to
intracranial arteries and arterioles. Others usuallybut not
alwayspresent with systemic manifestations by the time the
effects of cerebral involvement become clinically evident. Giant cell
arteritis, systemic lupus erythematosus, and
polyarteritis nodosa are examples of this group. These diseases are
etiologically and pathologically heterogeneous. Their
causes are poorly understood, and the bedside diagnosis is
problematic for lack of an accurate noninvasive test and
the relatively nonspecific nature of clinical manifestations. Because
of studies reporting favorable results with immunosuppressive therapy,
meningeal or cerebral biopsy is indicated in selected patients. The
mechanism of stroke varies: necrotizing vasculitis, hypercoagulable
state, artery-to-artery or cardiac embolism. An inflammatory
infiltration of the arterial wall can be seen in patients
with bacterial or tuberculous meningitis, cerebral cysticercosis,
fungal infection, and herpes zoster arteritis. Diagnosis and treatment
are specific for each instance.
Other Arterial Disease
Reviews of other arterial etiologies for stroke are
found elsewhere.
| Selected Reading |
|---|
|
|
|---|
Surgical Management of Large Artery Occlusive Disease
The North American Symptomatic Carotid Endartectomy Trial (NASCET)
demonstrated the benefit of surgery for patients with recent stroke or
TIA with extracranial internal carotid artery stenosis ranging from
70% to 99%. The beneficial results in stroke prevention were largely
dependent on the skill of the surgeons, who attained an acceptably low
rate (5.8%) of perioperative stroke and death. In a European study,
medical therapy was clearly superior to surgery at <30% stenosis.
Results are awaited for the moderate phase of NASCET, for stenosis
ranging from 30% to 69%.
The Asymptomatic Carotid Atherosclerosis Study (ACAS) demonstrated a
benefit for surgery for stenosis
60% with low rates of perioperative
complications. However, this conclusion is not universally accepted by
the stroke community. Some believe the rate of complications does not
warrant the 1% annual reduction in absolute risk of stroke.
The cooperative trials of carotid endarterectomy have not established whether the complication rates of the surgical arm would be even lower if the diagnostic workup was limited to duplex Doppler and magnetic resonance angiography instead of incurring the risk of conventional angiography. The risks and benefits of carotid angioplasty remain unsettled.
The hesitancy to perform carotid endarterectomy for acute stroke derives from an early study showing that more than 50% of such patients suffered a fatal intracranial hemorrhage within 72 hours of emergency carotid endarterectomy; many such complications at that time could be attributed to unrecognized postoperative hypertension. Angiographically demonstrated intraluminal thrombus is treated with administration of heparin followed by warfarin. In many patients the thrombus resolves without sequelae with medical therapy. Surgery for hyperacute complete carotid occlusion (hours to several days) may re-establish flow, depending on duration of the occlusion. Delayed surgery has had disappointing results.
Many cerebrovascular surgeons empirically recommend a delay of 3 to 6 weeks before performing carotid endarterectomy in patients with fresh but nondebilitating strokes (especially those with CT findings and presumed defective autoregulation); recent studies indicate neurologically stable patients probably have no greater surgical risk in the early poststroke period than patients with TIAs.
In an extensive study conducted a decade ago, external carotidinternal carotid (EC-IC) anastomoses were shown statistically to be no better than medical therapy. Brain resection after infarction is aimed at decompression during the acute period of brain swelling, when patient survival is deemed essential regardless of postoperative clinical syndrome severity. Decompressive surgery for cerebellar infarction can prevent sudden fatal posterior fossa compression syndromes, which are difficult to predict.
| Selected Reading |
|---|
|
|
|---|
Small Artery Occlusion
That small, deep cavitary (lacunar) infarcts are mainly due to
small arterial occlusions continues to be a fundamental
principle in the pathogenesis of small deep infarcts. Neuroimaging and
pathology indicate a continuum of cerebral histological
alteration due to small artery ischemia ranging from an
isolated focal loss of neurons to cavitary infarction with loss of all
tissue elements. In between these two extremes, ischemia may
cause a variable rarefaction of all tissue elements with
demyelination and axonal, neuronal, and oligodendroglial loss
associated with astrocytosis. Focal zones of ischemia
rarefactionnoncavitary, incomplete, or white matter infarctsare not
true infarcts histologically and may be caused by small
arterial narrowing. Large arterial occlusive
disease is probably also a cause.
Intrinsic Small Artery Disease
Microatheroma may be the most frequent pathology
underlying symptomatic lacunar infarcts. Lipohyalinosis or
segmental small arterial disorganization is a known cause
of occlusions of very small penetrating arteries (<200 µm) in
hypertensive persons and may give rise to small
asymptomatic lacunar infarcts. This pathology may also
underlie microaneurysms, a likely cause of
intracerebral hypertensive hemorrhage. Small
penetrating artery occlusion due to fibrinoid necrosis is occasionally
seen in hypertensive brains or vasculitides, but the relation to
cavitary infarction is unclear. Small artery pathologies are associated
with ischemic rarefaction in patients with subcortical
arteriosclerotic encephalopathy: hyaline
arteriosclerosis seen in elderly normotensive
persons, amyloid angiopathy which mainly involves the meningocortical
segments of penetrating arteries, and sclerosing vasculopathy. Small
granular arteriopathy associated with cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencephalopathy is
responsible for both ischemic rarefaction and small, deep
cavitary infarcts. This condition is dominantly inherited, and the gene
locus has now been mapped to within 2 centimorgans on chromosome
19q123.
Other Causes of Small Vessel Occlusion
Cardiogenic embolism has been established as a potential cause of
lacunar infarction. Lacunar infarcts have been found on autopsy in
patients with rheumatic heart disease and nonbacterial thrombotic
endocarditis. Artery-to-artery embolism is also an established cause of
lacunar infarction. Lacunar and small deep infarcts have been reported
as complications of aortic arch plaque or coronary angiography
and have resulted from cholesterol embolism from an aortic
dissection. There may be an association between carotid
stenosis and asymptomatic small deep infarcts. A
lacunar syndrome may thus be the first indication of a critical large
intracranial artery stenosis. Penetrating arteries supplying a
lacunar infarct may be stenosed but not occluded, making it likely that
these infarcts resulted from hypoperfusion. Small, deep infarcts at the
upper lateral borders of the lateral ventricles are in a deep watershed
territory, are seen with ipsilateral carotid occlusion, and are called
low-flow or internal watershed infarcts. Hypoperfusion caused by
narrowing of small white matter, long penetrating arteries is probably
the cause of subcortical arteriosclerotic
encephalopathy. Hemodynamically significant cardiac
disease may interact with stenosis of
intracerebral small arteries to increase the risk of
hypoperfusion injury. Small, deep infarcts may occasionally be seen in
patients with other vasculitides and prothrombotic conditions.
| Selected Reading |
|---|
|
|
|---|
| Thrombosis |
|---|
|
|
|---|
Prothrombotic States
Primary prothrombotic states include abnormalities of certain
hemostatic regulatory proteins, including the antithrombins, heparin
cofactor II, proteins C and S, and fibrinolytic system derangements.
Genetic defects of the regulatory hemostatic proteins that produce
prothrombotic states usually present clinically with thrombotic
episodes by the second or third decade of life, whereas acquired
deficiencies in these hemostatic proteins may be associated with stroke
at any age. Definitive studies of hemostatic disorders of large
populations of subjects with stroke are lacking.
In patients with prothrombotic states, other predisposing causes for stroke are not excluded. The plasma levels of antithrombins and proteins C and S may be reduced as a result of consumption in the thrombotic process, and repeat measurement can be obtained after 6 weeks when the acute phase has passed. Most patients with genetic causes of prothrombotic states who have had stroke require long-term anticoagulation with warfarin. For patients with protein C or S deficiency, treatment with heparin at the initiation of warfarin therapy is required to reduce the risk of necrotizing thrombosis of the skin.
Antiphospholipid antibodies (aPL) are associated with a syndrome of thrombosis, thrombocytopenia, fetal loss, and a variety of neurological manifestations but appear to be especially important with respect to recurrent cerebrovascular disease. aPL can be demonstrated indirectly by prolongation of phospholipid-dependent coagulation assays using platelet-poor plasma (lupus anticoagulant [LA] effect) or directly using an enzyme-linked immunosorbent assay (ELISA). There is an incomplete overlap for detection of aPL by these methods in an individual patient. Clinical aPL-related manifestations are considered primary if the patient does not have a diagnosis of systemic lupus erythematosus and secondary if systemic lupus erythematosus is present.
Antiphospholipid antibodies are an extremely heterogeneous group of antibodies directed against a variety of antigenic determinants: platelets, coagulation proteins, and endothelial cells. Cerebral ischemia associated with aPL is the most common arterial manifestation; however, the importance of aPL as a cardiovascular risk factor is controversial. In many studies aPL is associated with an increased risk for incidence and recurrence of cerebral ischemia, MI, and venous thrombosis. Intracardiac thrombus has been reported. Regardless of age, patients with cerebral ischemia often have other risk factors for cerebrovascular disease. aPL may act in concert with other vascular risk factors that damage endothelial cells. A variety of cardiac valvular lesions have been associated with aPL, and cardiac emboli are a possible cause of cerebrovascular symptoms. Any attempt to propose a standard form of treatment for aPL-associated thrombosis is premature at this time.
| Selected Reading |
|---|
|
|
|---|
Stroke due to intracranial parenchymatous hemorrhages is not discussed.
| Recommendations |
|---|
|
|
|---|
Patients with MI at high risk for systemic
embolization should receive oral anticoagulation at a target INR range
of 2.5 to 3.5 for 6 months or more.
Patients with cardiac valvular disorders,
prosthetic heart valves, and repaired valves have a
variable risk of ischemic stroke. Their need for
antiplatelet or anticoagulant therapy should be evaluated.
In the absence of a mobile thrombus, the presence of
aortic arch plaque >4 mm should be viewed as a marker of high
risk of recurrent stroke, MI, peripheral embolism, and
vascular death. The natural history of mobile aortic arch plaques,
development of new noninvasive techniques to define plaque composition,
and initiation of therapeutic trials may be topics for research in the
future.
When faced with lacunar infarction or syndrome, the
possibility of underlying large-vessel, especially intracranial,
cardiac source embolism and hypercoagulable state should be considered
as should small-vessel disease.
Carotid endarterectomy is beneficial
for patients with recent cerebral ischemia and ipsilateral
(nonocclusive) carotid artery stenosis of >70%. It is not
beneficial for patients with 0% to 29% stenosis, and it
remains uncertain if endarterectomy is beneficial
for stenosis of 30% to 69%.
Much work is needed to define the spectrum and role of
hypercoagulable states, including that of aPL, in stroke.
The etiology (hemorrhage, ischemia versus
nonstroke-related potential causes) of transient cerebral symptoms
should be diagnosed in every patient who experiences them. For those
for whom the cause is likely to be ischemic and who do not
require warfarin, the best dose of aspirin for stroke prophylaxis is
debated. Ticlopidine is more effective than aspirin, but the cost and
risk of adverse effects are higher.
| Footnotes |
|---|
This article has been cited by other articles:
![]() |
H. Kimm, J. E. Yun, J. Jo, and S. H. Jee Low Serum Bilirubin Level as an Independent Predictor of Stroke Incidence: A Prospective Study in Korean Men and Women Stroke, November 1, 2009; 40(11): 3422 - 3427. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Amarenco, O. Benavente, L. B. Goldstein, A. Callahan III, H. Sillesen, M. G. Hennerici, S. Gilbert, A. E. Rudolph, L. Simunovic, J. A. Zivin, et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes Stroke, April 1, 2009; 40(4): 1405 - 1409. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sillesen, P. Amarenco, M. G. Hennerici, A. Callahan, L. B. Goldstein, J. Zivin, M. Messig, K. M. Welch, and on Behalf of the SPARCL Investigators Atorvastatin Reduces the Risk of Cardiovascular Events in Patients With Carotid Atherosclerosis: A Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial Stroke, December 1, 2008; 39(12): 3297 - 3302. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Amarenco and P. G. Steg Stroke is a coronary heart disease risk equivalent: implications for future clinical trials in secondary stroke prevention Eur. Heart J., July 1, 2008; 29(13): 1605 - 1607. [Full Text] [PDF] |
||||
![]() |
U. K. Sampson, M. A. Pfeffer, J. J.V. McMurray, Y. Lokhnygina, H. D. White, S. D. Solomon, and for the Valsartan in Acute Myocardial iNfarcTion ( Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT trial Eur. Heart J., March 2, 2007; 28(6): 685 - 691. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Alberts, R. E. Latchaw, W. R. Selman, T. Shephard, M. N. Hadley, L. M. Brass, W. Koroshetz, J. R. Marler, J. Booss, R. D. Zorowitz, et al. Recommendations for Comprehensive Stroke Centers: A Consensus Statement From the Brain Attack Coalition Stroke, July 1, 2005; 36(7): 1597 - 1616. [Abstract] [Full Text] [PDF] |
||||
![]() |
Measuring and Improving Quality of Care : A Report From the American Heart Association/American College of Cardiology First Scientific Forum on Assessment of Healthcare Quality in Cardiovascular Disease and Stroke Stroke, April 1, 2000; 31(4): 1002 - 1012. [Full Text] [PDF] |
||||
![]() |
Measuring and Improving Quality of Care : A Report From the American Heart Association/American College of Cardiology First Scientific Forum on Assessment of Healthcare Quality in Cardiovascular Disease and Stroke Circulation, March 28, 2000; 101(12): 1483 - 1493. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |